[ad_1]
Check-in 2021.01.27 10:53
German government “There is insufficient data on clinical trials for older people compared to other pharmaceutical companies”
The European Medicines Agency reviewed that vaccination was allowed only for certain age groups, except for the elderly.
The efficacy of the vaccine remains controversial … Question of the possibility of forming group immunity.
The controversy over AstraZeneca’s Corona 19 vaccine, which Korea has contracted to import, rarely subsides despite aggressive clarification from the company. Following a German media report that AstraZeneca vaccine is only 8% effective in the age group over 65, some point out that AstraZeneca did not properly design clinical trials for older people compared to other pharmaceutical companies.
According to the Financial Times (FT) and The Guardian on the 26th (local time), the German government recently announced that the controversy over the effectiveness of AstraZeneca’s vaccine against the elderly, raised by local media, is not true. AstraZeneca also issued an official statement saying the report was completely wrong. However, the German government noted that it is also clear that AstraZeneca’s clinical data should be questioned.
That does not mean that the German government is giving full confidence in AstraZeneca’s COVID-19 vaccine. According to FT, a German government official is concerned by AstraZeneca’s vaccine efficacy data that “clinical data provided by AstraZeneca is less effective for the elderly than clinical data from other manufacturers (Pfizer, Modena, etc.) “. He even made a voice.
The controversy over the AstraZeneca vaccine has continued since last year. In particular, it has been noted that in Australia it is difficult to build population immunity with the AstraZeneca vaccine. According to each manufacturer’s announcement, the Pfizer and Modena vaccine showed an efficacy of around 95% in phase 3 clinical trials, while the AstraZeneca vaccine showed an efficacy of 62% when all doses were administered.
According to foreign media, Andrew Miller, President of the Western Australian Medical Association, said: “Until more evidence is available that the AstraZeneca vaccine is as effective as other vaccines, there is a risk that the AstraZeneca vaccine will not achieve the immunity of the population “. “Australia has controlled Corona 19 well, so there is time to wait for the best vaccine to build public trust. Why should we be satisfied with the next best option?”
Some are leading to the possibility of discontinuing AstraZeneca vaccination for the elderly. According to British Guardian and BBC Broadcasting, the Commissioner of the European Medicines Agency (EMA) attended the European Parliament’s Health Commission on the 26th (local time) to answer questions from legislators, excluding the possibility of approving the vaccine. AstraZeneca only for a certain age. groups. I did not do it.
“We don’t want to get confused because there is an ongoing scientific and professional discussion,” he said. “There is a possibility that a conclusion may be reached to approve the use by focusing on a specific age group, and a conclusion may be drawn to address a broader range of age groups.
Commissioner Cook noted that studies have been conducted in only a small number of people to date on whether the AstraZeneca vaccine is effective for the elderly. We are trying to find out what to expect (at the time of vaccination), “he added.
Meanwhile, AstraZeneca countered the suspicion head-on, stating that its vaccine is also effective in the elderly. In an official statement, AstraZeneca stated that according to data published in the Lancet, the elderly also showed strong immune responses, including 100% antibody formation after the second vaccination. He highlighted that the Joint Committee on Vaccination and Immunization (JCVI) in the UK has approved the use of older people.
